Drug Profile
BI 1206
Alternative Names: 6G 11; BI-1206Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator BioInvent International
- Developer BioInvent International; CASI Pharmaceuticals; Merck Sharp & Dohme; University of Southampton
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Fc gamma receptor IIB antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours
- No development reported Mantle-cell lymphoma
Most Recent Events
- 05 Mar 2024 Efficacy and adverse event data from a phase I trial in Non-Hodgkin's lymphoma released by CASI Pharmaceuticals
- 28 Jan 2024 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in Sweden (Parenteral)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in USA (Parenteral)